Back to discover
§ The cross-read
GILD vs VRTX
GILD's Section-2 aggressive Pricing Reform risk is the dominant variable in any cross-read.
Fair-value ladder
Fair-value ladder unavailable — one or both tickers have no published mid fair value.
Aligned scorecards
GILDVRTX
| GILDGilead Sciences Inc. | VRTXVertex Pharmaceuticals Incorporated | |
|---|---|---|
| Trend | - | - |
| Price | - | - |
| Fair value | - | - |
| FV range | - | - |
| Upside | - | - |
| Rating | 持有 | 持有 |
| Confidence | - | - |
| Moat | - | - |
| Archetype | - | - |
| Sector | Health Care | Health Care |
| Analyzed | - | - |
9-category scorecards
GILD
Gilead Sciences Inc.
Valuation
5.0/10
0.11x
Management
7.3/10
0.11x
Balance Sheet
6.0/10
0.11x
Profitability
8.5/10
0.11x
Revenue Growth
4.5/10
0.11x
Risk Assessment
7.0/10
0.11x
Competitive Moat
6.5/10
0.11x
Earnings Quality
7.5/10
0.11x
Capital Efficiency
7.5/10
0.11x
Weighted Overall
6.6/10
VRTX
Vertex Pharmaceuticals Incorporated
Valuation
5.0/10
0.11x
Management
7.3/10
0.11x
Balance Sheet
8.5/10
0.11x
Profitability
7.5/10
0.11x
Revenue Growth
6.0/10
0.11x
Risk Assessment
9.0/10
0.11x
Competitive Moat
9.0/10
0.11x
Earnings Quality
7.5/10
0.11x
Capital Efficiency
7.5/10
0.11x
Weighted Overall
7.5/10